

329  
SUB C22

139. (Amended) The attenuated tumor targeted bacteria of claim 13, wherein the pro-drug converting enzyme is cytosine deaminase.


**REMARKS**

Claims 2-14, 16, 26-38, 40, 49-60, 61, 63, 72-84, 86, 94, 100-141 were pending in this application. Claims 3, 5, 7, 9, 11-14, 16, 27, 29, 31, 33, 35-38, 40, 50, 52, 54, 56, 58-61, 63, 73, 75, 77, 79, 81-84, 100-102, 104, 113, 126, 139 have been amended to correct dependencies of the claims in accordance with canceled claims. A copy of the claims which will be pending upon entry of the instant Amendment is attached hereto as Exhibit A. A marked-up version of the amended claims indicating the changes is attached hereto as Exhibit B. No new matter has been added.


Applicants respectfully request entry of the amendments and remarks made herein into the file history of the present application.

Respectfully submitted,

Date November 8, 2002

  
Geraldine F. Baldwin (Reg. No.) 31,232

**PENNIE & EDMONDS** LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090



RECEIVED  
NOV 14 2002  
TECH CENTER 1600/2900

EXHIBIT B

MARKED-UP VERSION OF AMENDED CLAIMS

U.S. PATENT APPLICATION SERIAL NO. 09/645,415

---

3. (Amended) The attenuated tumor-targeted bacteria of claim [1 or] 2, wherein at least one of the primary effector molecules is a TNF family member.
- ~~5. (Amended) The attenuated tumor-targeted bacteria of claim [1 or] 2, wherein at least one of the primary effector molecules is an anti-angiogenic factor.~~
7. (Amended) The attenuated tumor-targeted bacteria of claim [1 or] 2, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.
9. (Amended) The attenuated tumor targeted bacteria of claim [1 or] 2, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.
11. (Amended) The attenuated tumor targeted bacteria of claim [1 or] 2, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2, or PMT.
12. (Amended) The attenuated tumor-targeted bacteria of claim [1 or] 2, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.
14. (Amended) The attenuated tumor-targeted bacteria of claim [1 or] 2, wherein the attenuated tumor-targeted bacteria is *Salmonella*.
16. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

27. (Amended) The pharmaceutical composition of claim [25 or] 26, wherein at least one of the primary effector molecules is a TNF family member.

29. (Amended) The pharmaceutical composition of claim [25 or] 26, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

31. (Amended) The pharmaceutical composition of claim [25 or] 26, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

33. (Amended) The pharmaceutical composition of claim [25 or] 26, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

35. (Amended) The pharmaceutical composition of claim [25 or] 26, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2, or PMT.

36. (Amended) The pharmaceutical composition of claim [25 or] 26, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

37. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the secondary effector molecules is an immunomodulating agent, an anti-tumor protein, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

38. (Amended) The pharmaceutical composition of claim [25 or] 26, wherein the attenuated tumor-targeted bacteria is *Salmonella*.

40. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

50. (Amended) The method of claim [48 or] 49, wherein at least one of the primary effector molecules is a TNF family member.

52. (Amended) The method of claim [48 or] 49, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

54. (Amended) The method of claim [48 or] 49, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

56. (Amended) The method of claim [48 or] 49, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

58. (Amended) The method of claim [48 or] 49, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2 or PMT.

59. (Amended) The method of claim [48 or] 49, wherein at least one of the primary effector molecules are derived from an animal, plant, bacteria, or virus.

60. (Twice Amended) The method of claim 49, wherein at least one of the secondary effector molecules is an anti-tumor protein, an immunomodulating agent, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

61. (Amended) The method of claim [48 or] 49, wherein the attenuated tumor-targeted bacteria is *Salmonella*.

73. (Amended) The method of claim [71 or] 72, wherein at least one of the primary effector molecules is a TNF family member.

75. (Amended) The method of claim [71 or] 72, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

77. (Amended) The method of claim [71 or] 72, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

79. (Amended) The method of claim [71 or] 72, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

81. (Amended) The method of claim [71 or] 72, wherein at least one of the primary effector molecule is hemolysin, verotoxin, CNF1, CNF2, or PMT.

82. (Amended) The method of claim [71 or] 72, wherein the primary effector molecule is derived from an animal, plant, bacteria, or virus.

83. (Amended) The method of claim [82] 72, wherein at least one of the secondary effector molecules is an immunomodulating agent, an anti-tumor protein, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

84. (Amended) The method of claim [71 or] 72, wherein the attenuated tumor-targeted bacteria is *Salmonella*.

101. (Amended) The attenuated tumor targeted bacteria of claim [2] 13, wherein the antisense molecule is double-stranded or single-stranded DNA, double-stranded or single-stranded RNA, or a triplex molecule.

102. (Amended) The attenuated tumor targeted bacteria of claim [2] 13, wherein the anti-tumor protein is a ribosome inactivating protein.

104. (Amended) The attenuated tumor targeted bacteria of claim [2] 13, wherein the pro-drug converting enzyme is cytochrome p450 NADPH oxidoreductase.

113. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the secondary effector molecules is a release factor.

126. (Amended) The method of claim 49, wherein at least one of the secondary effector molecules is a release factor.

139. (Amended) The attenuated tumor targeted bacteria of claim [2] 13, wherein the pro-drug converting enzyme is cytosine deaminase.